Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries

Emerging Microbes and Infections

Volumn 7, Issue 1, 2018, Pages

  Xie, Ruiqiang ^a   Zhang, Xiaohua Douglas ^a   Zhao, Qi ^a   Peng, Bo ^b,c   Zheng, Jun ^a  

^a University of Macau   (Macao)

^b SUN YAT SEN UNIVERSITY   (China)

^c QINGDAO NATIONAL LABORATORY FOR MARINE SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; COLISTIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT; MINOCYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; HUMAN; NONHUMAN; ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT; PREVALENCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT; PREVALENCE;

EID: 85044183388     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/s41426-018-0038-9     Document Type: Article

References (34)

1. O'Neill, J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev. Antimicrob. Resist. 20, 1-16 (2014).
2. de Kraker, M. E., Stewardson, A. J. & Harbarth, S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 13, e1002184 (2016).
3. Boucher, H. W. et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
4. Organization WHO. WHO Publishes List of Bacteria for which New Antibiotics are Urgently Needed. (WHO, Geneva, 2017). http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/.
5. Antunes, L. C., Visca, P. & Towner, K. J. Acinetobacter baumannii: evolution of a global pathogen. Pathog. Dis. 71, 292-301 (2014).
6. D'Arezzo, S. et al. Epidemic multidrug-resistant Acinetobacter baumannii related to European clonal types I and II in Rome (Italy). Clin. Microbiol. Infect. 15, 347-357 (2009).
7. Potron, A., Poirel, L. & Nordmann, P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int. J. Antimicrob. Agents 45, 568-585 (2015).
8. Nation, R. L. et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect. Dis. 15, 225-234 (2015).
9. Qureshi, Z. A. et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin. Infect. Dis. 60, 1295-1303 (2015).
10. Morgan, D. J. et al. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect. Dis. 11, 692-701 (2011).
11. Cizman, M. et al. Antibiotic policies in Central Eastern Europe. Int. J. Antimicrob. Agents 24, 199-204 (2004).
12. Fishbain, J. & Peleg, A. Y. Treatment of acinetobacter infections. Clin. Infect. Dis. 51, 79-84 (2010).
13. Bryce, A. et al. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ 352, i939 (2016).
14. Higgins, J. P. & Green, S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The cochrane collaboration 5, (2011). www.handbook. cochrane.org.
15. Moher, D. et al. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ 339, b2535 (2009).
16. Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 36, 1-48 (2010).
17. Tasina, E. et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect. Dis. 11, 834-844 (2011).
18. Ni, W. et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int. J. Antimicrob. Agents 47, 107-116 (2016).
19. Fitzpatrick, M. A. et al. Influence of ACB complex genospecies on clinical outcomes in a U.S. hospital with high rates of multidrug resistance. J. Infect. 70, 144-152 (2015).
20. Karlowsky, J. A. et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47, 1681-1688 (2003).
21. Tan, R. et al. Epidemiology and antimicrobial resistance among commonly encountered bacteria associated with infections and colonization in intensive care units in a university-affiliated hospital in Shanghai. J. Microbiol. Immunol. Infect. 47, 87-94 (2014).
22. Mahamat, A. et al. Clinical epidemiology and resistance mechanisms of carbapenem-resistant Acinetobacter baumannii, French Guiana, 2008-2014. Int. J. Antimicrob. Agents 48, 51-55 (2016).
23. Gogou, V. et al. Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: a 10 year study in Greece (2000-09). J. Antimicrob. Chemother. 66, 2767-2772 (2011).
24. Villalon, P. et al. Clonal diversity of nosocomial epidemic Acinetobacter baumannii strains isolated in Spain. J. Clin. Microbiol. 49, 875-882 (2011).
25. Da Silva, G. J. et al. Sequence types of Portuguese carbapenem-resistant Acinetobacter baumannii isolates collected over 10 years. J. Antimicrob. Chemother. 65, 2254-2256 (2010).
26. Di Popolo, A. et al. Molecular epidemiological investigation of multidrugresistant Acinetobacter baumannii strains in four Mediterranean countries with a multilocus sequence typing scheme. Clin. Microbiol. Infect. 17, 197-201 (2011).
27. Diancourt, L. et al. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One 5, e10034 (2010).
28. van Dessel, H. et al. Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res. Microbiol. 155, 105-112 (2004).
29. Pourhajibagher, M. et al. Antimicrobial resistance of Acinetobacter baumannii to Imipenem in Iran: a systematic review and meta-analysis. Open Microbiol. J. 10, 32-42 (2016).
30. Canton, R. et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18, 413-431 (2012).
31. Yilmaz, G. et al. Characterization and toxicity of hospital wastewaters in Turkey. Environ. Monit. Assess. 189, 55 (2017).
32. Maraki, S. et al. Epidemiology and antimicrobial sensitivities of 536 multi-drugresistant gram-negative bacilli isolated from patients treated on surgical wards. Surg. Infect. 13, 326-331 (2012).
33. Lazureanu, V. et al. Infection with Acinetobacter baumannii in an intensive care unit in the Western part of Romania. BMC Infect. Dis. 16, 95 (2016).
34. Lesho, E. et al. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J. Infect. Dis. 208, 1142-1151 (2013).